TapewireFind a company

person · Reporting owner

Adar Almog

Disclosed activity across 1 company

Tapewire entity
55557
SEC CIK
0001919473

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Lifeward Ltd.LFWD · Entity 7620Chief Financial OfficerMarch 25, 2026March 27, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Lifeward Ltd.

Report date March 25, 2026 · Filed March 27, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.53 · Expires 2036-03-25Direct39,934 Reported balance After 2026-03-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-03-25 · Grant · Acquired 39,934 · Balance 39,934

F1: The shares underlying the option shall become vested and exercisable over four (4) years with 25% of the shares vesting on March 25, 2027, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, provided the reporting person's continued service with the Company on each applicable vesting date, subject to acceleration as provided in the applicable plan and non-qualified stock option grant. .

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying the option shall become vested and exercisable over four (4) years with 25% of the shares vesting on March 25, 2027, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, provided the reporting person's continued service with the Company on each applicable vesting date, subject to acceleration as provided in the applicable plan and non-qualified stock option grant. .

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 25, 2026 Filed Mar 27, 2026 20:59 UTC Lifeward Ltd. LFWD · Entity 7620 GrantOption (Right to Buy) · Derivative 39,934 $0.00 Strike: $6.53 $0.00
Disclosure

SEC source: 0001178913-26-001820 · ownership.xml · derivative · entry 1

Adar Almog · CIK 0001919473 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,934

Underlying: Ordinary Shares, no par value per share · 39,934 shares

Expires 2036-03-25

F1 · derivative.exercise_date: The shares underlying the option shall become vested and exercisable over four (4) years with 25% of the shares vesting on March 25, 2027, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, provided the reporting person's continued service with the Company on each applicable vesting date, subject to acceleration as provided in the applicable plan and non-qualified stock option grant. .

Read SEC document
August 13, 2025 Filed Aug 13, 2025 21:44 UTC Lifeward Ltd. LFWD · Entity 7620 GrantOption (Right to Buy) · Derivative 225,000 $0.00 Strike: $0.72 $0.00
Disclosure

SEC source: 0001062993-25-014315 · form4.xml · derivative · entry 1

Adar Almog · CIK 0001919473 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Ordinary Shares, par value NIS 1.75 per share · 225,000 shares

Expires 2035-08-13

F1 · derivative.exercise_date: Represents stock options granted under the 2025 Incentive Compensation Plan on August 13, 2025. The option shall vest and become exercisable in four equal annual installments beginning on August 13, 2026, subject to the Reporting Person's continued service as of each such vesting date.

Read SEC document
June 30, 2023 Filed Jul 3, 2023 20:46 UTC Lifeward Ltd. RWLK · Entity 7620 GrantOrdinary Shares, par value NIS 0.25 per share 125,000 $0.00 $0.00
Disclosure

SEC source: 0001062993-23-014345 · form4.xml · nonDerivative · entry 1

Adar Almog · CIK 0001919473 · VP of Finance

10b5-1 filing: No plan indicated

Ownership: Indirect · ESOP

Disclosed balance after: 262,500

F1 · shares: Represents 125,000 ordinary shares, par value NIS 0.25 per share, issuable upon the vesting of restricted stock units ("RSUs") granted on June 30, 2023 (the "Grant Date") under the ReWalk Robotics Ltd. (the "Company") Amended and Restated 2014 Incentive Compensation Plan. The RSUs vest ratably in four equal annual installments commencing as of the Grant Date.

Read SEC document
August 02, 2022 Filed Aug 3, 2022 20:04 UTC Lifeward Ltd. RWLK · Entity 7620 GrantOrdinary Shares, par value NIS 0.25 per share 100,000 $0.00 $0.00
Disclosure

SEC source: 0001062993-22-017162 · form4.xml · nonDerivative · entry 1

Adar Almog · CIK 0001919473 · Director of Finance

10b5-1 filing: Not disclosed

Ownership: Indirect · ESOP

Disclosed balance after: 137,500

F1 · shares: Represents 100,000 ordinary shares, par value NIS 0.25 per share, issuable upon the vesting of restricted stock units ("RSUs") granted on August 2, 2022 under the ReWalk Robotics Ltd. Amended and Restated 2014 Incentive Compensation Plan. The RSUs vest ratably in four equal annual installments, commencing as of August 2, 2022.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.